Casirivimab 60 mg/ML / imdevimab 60 mg/ML [Regen-Cov]
RxNorm 2557238

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2557238 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: casirivimab 60 mg/ML / imdevimab 60 mg/ML [Regen-Cov].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Casirivimab 60 mg/ML / imdevimab 60 mg/ML [Regen-Cov]
AUI:12646291
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDC

Semantic Branded Drug Component (SBDC):
Casirivimab 60 mg/ML / imdevimab 60 mg/ML [Regen-Cov]
(Atom ID: 12646291)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
casirivimab 60 MG/ML / imdevimab 60 MG/ML [Regen-Cov]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2557238
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12646291
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2557238
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN OBSOLETED
02/24/2025
Date the RxNorm atom became obsolete

Patient Education

Casirivimab and Imdevimab Injection


The combination of casirivimab and imdevimab is used in certain non-hospitalized adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) and who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms, including hospitalization or death: to treat mild to moderate symptoms of COVID-19. to prevent COVID-19 in those who are not fully vaccinated against COVID-19 or who are vaccinated, but have a weakened immune system, or are taking a medication that affects the immune system and who have had close contact or are at high risk of close contact to someone who is infected with the SARS-CoV-2 virus. Casirivimab and imdevimab are in a class of medications called monoclonal antibodies. They work by blocking the action of a certain natural substance in the body in order to stop the spread of the virus.
[Learn More]


* Please review the disclaimer below.